Research ExplorerPublicationsComparison of Anti-factor Xa Levels in Female and Male Patie...

Comparison of Anti-factor Xa Levels in Female and Male Patients with Obesity After Enoxaparin Application for Thromboprophylaxis

Standard

Comparison of Anti-factor Xa Levels in Female and Male Patients with Obesity After Enoxaparin Application for Thromboprophylaxis. / Wagner, Jonas; Wruck, Henrike; Lautenbach, Anne; von Kroge, Philipp; Wolter, Stefan; Mann, Oliver; Izbicki, Jakob; Duprée, Anna.

In: OBES SURG, Vol. 32, No. 3, 03.2022, p. 861-867.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Wagner, J, Wruck, H, Lautenbach, A, von Kroge, P, Wolter, S, Mann, O, Izbicki, J & Duprée, A 2022, 'Comparison of Anti-factor Xa Levels in Female and Male Patients with Obesity After Enoxaparin Application for Thromboprophylaxis', OBES SURG, vol. 32, no. 3, pp. 861-867. https://doi.org/10.1007/s11695-021-05875-z

APA

Wagner, J., Wruck, H., Lautenbach, A., von Kroge, P., Wolter, S., Mann, O., Izbicki, J., & Duprée, A. (2022). Comparison of Anti-factor Xa Levels in Female and Male Patients with Obesity After Enoxaparin Application for Thromboprophylaxis. OBES SURG, 32(3), 861-867. https://doi.org/10.1007/s11695-021-05875-z

Vancouver

Wagner J, Wruck H, Lautenbach A, von Kroge P, Wolter S, Mann O et al. Comparison of Anti-factor Xa Levels in Female and Male Patients with Obesity After Enoxaparin Application for Thromboprophylaxis. OBES SURG. 2022 Mar;32(3):861-867. https://doi.org/10.1007/s11695-021-05875-z

Bibtex

@article{61a631078e53453d9c4c606087e3ac03,
title = "Comparison of Anti-factor Xa Levels in Female and Male Patients with Obesity After Enoxaparin Application for Thromboprophylaxis",
abstract = "PURPOSE: Venous thromboembolic events (VTEs) are common complications after bariatric surgery, and enoxaparin is commonly used to prevent VTEs. The risk for VTEs is sex-specific. Whether enoxaparin application results in similar anti-factor Xa activities (aFXa) in males and females with obesity remains to be determined. We investigated whether our dosage regimen of enoxaparin resulted in similar serum aFXa levels in female and male patients undergoing bariatric surgery.MATERIALS AND METHODS: We administered enoxaparin twice daily in patients undergoing bariatric surgery. Patients with a body mass index (BMI) > 60 kg/m2 (n = 11) received 60 mg enoxaparin (group 2), and patients with lower BMI (n = 86) received 40 mg per dose (group 1). Peak aFXa levels were measured 3 days after surgery. The primary outcome was the aFXa level. As a secondary outcome, we detected VTEs and major bleeding events and explored the possible influencing factors of aFXa.RESULTS: Women had higher aFXa than men, but after matching for anthropometric values, the two groups were similar (females: 0.17 ± 0.08 U/ml; males: 0.18 ± 0.08 U/ml). Linear regression revealed a moderate relationship between weight and aFXa levels. The 3-month follow-up was attended by 94.9%, at which one patient had pulmonary embolism.CONCLUSION: Individual enoxaparin dosage regimens for men and women do not seem to be required. Weight-based dosing regimen seems to be a more reasonable choice.",
keywords = "Anticoagulants/therapeutic use, Drug Administration Schedule, Enoxaparin/therapeutic use, Factor Xa Inhibitors/therapeutic use, Female, Humans, Male, Obesity/complications, Obesity, Morbid/surgery, Prospective Studies, Venous Thromboembolism/etiology",
author = "Jonas Wagner and Henrike Wruck and Anne Lautenbach and {von Kroge}, Philipp and Stefan Wolter and Oliver Mann and Jakob Izbicki and Anna Dupr{\'e}e",
note = "{\textcopyright} 2022. The Author(s).",
year = "2022",
month = mar,
doi = "10.1007/s11695-021-05875-z",
language = "English",
volume = "32",
pages = "861--867",
journal = "OBES SURG",
issn = "0960-8923",
publisher = "Springer New York",
number = "3",

}

RIS

TY - JOUR

T1 - Comparison of Anti-factor Xa Levels in Female and Male Patients with Obesity After Enoxaparin Application for Thromboprophylaxis

AU - Wagner, Jonas

AU - Wruck, Henrike

AU - Lautenbach, Anne

AU - von Kroge, Philipp

AU - Wolter, Stefan

AU - Mann, Oliver

AU - Izbicki, Jakob

AU - Duprée, Anna

N1 - © 2022. The Author(s).

PY - 2022/3

Y1 - 2022/3

N2 - PURPOSE: Venous thromboembolic events (VTEs) are common complications after bariatric surgery, and enoxaparin is commonly used to prevent VTEs. The risk for VTEs is sex-specific. Whether enoxaparin application results in similar anti-factor Xa activities (aFXa) in males and females with obesity remains to be determined. We investigated whether our dosage regimen of enoxaparin resulted in similar serum aFXa levels in female and male patients undergoing bariatric surgery.MATERIALS AND METHODS: We administered enoxaparin twice daily in patients undergoing bariatric surgery. Patients with a body mass index (BMI) > 60 kg/m2 (n = 11) received 60 mg enoxaparin (group 2), and patients with lower BMI (n = 86) received 40 mg per dose (group 1). Peak aFXa levels were measured 3 days after surgery. The primary outcome was the aFXa level. As a secondary outcome, we detected VTEs and major bleeding events and explored the possible influencing factors of aFXa.RESULTS: Women had higher aFXa than men, but after matching for anthropometric values, the two groups were similar (females: 0.17 ± 0.08 U/ml; males: 0.18 ± 0.08 U/ml). Linear regression revealed a moderate relationship between weight and aFXa levels. The 3-month follow-up was attended by 94.9%, at which one patient had pulmonary embolism.CONCLUSION: Individual enoxaparin dosage regimens for men and women do not seem to be required. Weight-based dosing regimen seems to be a more reasonable choice.

AB - PURPOSE: Venous thromboembolic events (VTEs) are common complications after bariatric surgery, and enoxaparin is commonly used to prevent VTEs. The risk for VTEs is sex-specific. Whether enoxaparin application results in similar anti-factor Xa activities (aFXa) in males and females with obesity remains to be determined. We investigated whether our dosage regimen of enoxaparin resulted in similar serum aFXa levels in female and male patients undergoing bariatric surgery.MATERIALS AND METHODS: We administered enoxaparin twice daily in patients undergoing bariatric surgery. Patients with a body mass index (BMI) > 60 kg/m2 (n = 11) received 60 mg enoxaparin (group 2), and patients with lower BMI (n = 86) received 40 mg per dose (group 1). Peak aFXa levels were measured 3 days after surgery. The primary outcome was the aFXa level. As a secondary outcome, we detected VTEs and major bleeding events and explored the possible influencing factors of aFXa.RESULTS: Women had higher aFXa than men, but after matching for anthropometric values, the two groups were similar (females: 0.17 ± 0.08 U/ml; males: 0.18 ± 0.08 U/ml). Linear regression revealed a moderate relationship between weight and aFXa levels. The 3-month follow-up was attended by 94.9%, at which one patient had pulmonary embolism.CONCLUSION: Individual enoxaparin dosage regimens for men and women do not seem to be required. Weight-based dosing regimen seems to be a more reasonable choice.

KW - Anticoagulants/therapeutic use

KW - Drug Administration Schedule

KW - Enoxaparin/therapeutic use

KW - Factor Xa Inhibitors/therapeutic use

KW - Female

KW - Humans

KW - Male

KW - Obesity/complications

KW - Obesity, Morbid/surgery

KW - Prospective Studies

KW - Venous Thromboembolism/etiology

U2 - 10.1007/s11695-021-05875-z

DO - 10.1007/s11695-021-05875-z

M3 - SCORING: Journal article

C2 - 34988894

VL - 32

SP - 861

EP - 867

JO - OBES SURG

JF - OBES SURG

SN - 0960-8923

IS - 3

ER -